Kyungnam Pharm Co., Ltd.

As of March 31, 2026, Kyungnam Pharm Co., Ltd. carries a market capitalization of 69.18B, placing it among publicly traded companies globally. Its enterprise value stands at 70.09B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Kyungnam Pharm Co., Ltd. has 17.45M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 1.14, and the price-to-book ratio stands at 0.64.

As of March 31, 2026, Kyungnam Pharm Co., Ltd. trades at an EV/EBITDA multiple of 1,634.08 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.19 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 70.09B versus a market cap of 69.18B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Kyungnam Pharm Co., Ltd. maintains a current ratio of 1.75, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 28.90, indicating elevated leverage, while an interest coverage ratio of 0.05 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Kyungnam Pharm Co., Ltd. posted a negative return on equity (ROE) of -7.36, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -4.84, reflecting losses generated across the asset base. The company generates approximately 236.87M in revenue per employee across its workforce of 249.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.11 indicates how many times Kyungnam Pharm Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Kyungnam Pharm Co., Ltd. recorded 295.88M in income tax expense. The company reported a pretax loss of -8.00B and -8.14B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Kyungnam Pharm Co., Ltd.'s stock has declined approximately 37.49% over the past 52 weeks. The 50-day moving average sits at 1,901.36, while the 200-day moving average is 2,619.07.

Over the twelve months ended March 31, 2026, Kyungnam Pharm Co., Ltd. generated 58.98B in revenue and converted that into -8.14B in net income, yielding earnings per share of -488.29. EBITDA reached 42.89M, while operating income came in at -1.46B.

As of March 31, 2026, Kyungnam Pharm Co., Ltd. holds 52.78B in cash and equivalents against 36.24B in total debt, resulting in a net debt position of 13.57B. Total book value stands at 107.93B, with working capital of 37.00B providing operational flexibility.

These figures cover the twelve months ended March 31, 2026.

Over the twelve months ended March 31, 2026, Kyungnam Pharm Co., Ltd. posted a gross margin of 27.08, reflecting its pricing power and cost economics. The operating margin of -2.48 and net profit margin of -13.81 provide insight into operational efficiency.

Kyungnam Pharm Co., Ltd.'s most recent stock split took place on May 7, 2026 with a 5:1 split ratio.

As of March 31, 2026, Kyungnam Pharm Co., Ltd. has an Altman Z-Score of 1.15, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.